CJC-1295 and Ipamorelin in the GH–IGF-1 Axis Literature: What Published Reviews Report

CJC-1295 and ipamorelin are frequently discussed together in the published literature on peptides that modulate the growth hormone–insulin-like growth factor-1 (GH–IGF-1) axis. A 2026 narrative review in Frontiers in Endocrinology grouped these compounds within a broader set of agents marketed as "research compounds," placing CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC in the growth hormone-releasing hormone (GHRH) analogue class alongside sermorelin and tesamorelin, and placing ipamorelin in the growth hormone secretagogue (GHS) class alongside GHRP-2, GHRP-6, and hexarelin [1]. That review also situated related agents in the same landscape, including the GH fragment AOD9604 (hGH 176-191) and IGF-1 analogues such as PEG-MGF and IGF-1 LR3 [1]. A central feature of both reviews is how they rank the available human evidence. The Frontiers in Endocrinology review explicitly stratified these peptides into evidence tiers ranging from regulatory-grade randomised trial data down to a complete absence of human studies, and stated that this stratification leaves substantial uncertainty around putative performance and body-recomposition effects [1]. A 2026 structured narrative review in JBJS Reviews, which searched PubMed/MEDLINE, Embase, and Web of Science for human and translational work published between January 2020 and August 2025, reached a convergent characterisation: it described growth hormone axis secretagogues, naming CJC-1295, ipamorelin, and tesamorelin, as remaining investigational, with uncertain safety profiles and product-quality concerns [2]. In that review's taxonomy, only glucagon-like peptide-1 receptor agonists were described as supported by reproducible randomised human evidence in the musculoskeletal indication studied, while structural cartilage modification was described as unproven [2]; the growth hormone axis secretagogues were not assigned that level of support [2]. The JBJS Reviews synthesis was graded Level V evidence with a predominantly C strength-of-recommendation taxonomy, which is relevant context for how researchers should weight its conclusions [2]. On reported harms, the Frontiers in Endocrinology review synthesised adverse effects described across this peptide class in clinical practice and in online self-administration settings. The reported domains spanned endocrine and metabolic disturbances, including prolactin and cortisol elevations, appetite changes, and dysglycaemia; fluid retention syndromes; musculoskeletal symptoms such as myalgia and arthralgia; and injection-site reactions [1]. The same review discussed biologically plausible but unproven mitogenic concerns as an area of residual uncertainty rather than an established finding [1]. It also noted that the composition, stated dose, and stacking practices of products obtained through unregulated supply chains are themselves uncertain, which complicates interpretation of both symptoms and laboratory abnormalities in people presenting after exposure [1]. Both reviews address the regulatory and antidoping context. The Frontiers in Endocrinology review noted the absence of regulatory approval for physique- or performance-related indications and proposed a clinically oriented assessment algorithm intended to support exposure-history taking and symptom triage without legitimising off-label peptide regimens [1]. The JBJS Reviews paper reported widespread antidoping restrictions on the growth hormone axis secretagogue class and concluded that injectable peptides in sports medicine remain largely experimental, with use appropriately confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols [2]. Neither review reported a controlled human trial of a CJC-1295 plus ipamorelin combination; both instead described the class as characterised by a gap between clinical evidence and self-administration practice [1][2].